4 New Drugs Approved for Primary Care: Q3 2022

October 6, 2022

The third quarter has come and gone, which means Patient Care Online has compiled another list of drugs approved by the US Food and Drug Administration for conditions that are often seen in primary care. In the slides below, find details on a novel rapid-acting treatment for major depressive disorder that was the first of its kind to receive approval from FDA, a novel treatment for plaque psoraisis, and more.

Plaque Psoriasis: Roflumilast Cream (Zoryve^®)(formerly ARQ-151)

The first and only topical phosphodiesterase 4 inhibitor approved for the topical treatment of plaque psoriasis. It is indicated for patients aged ≥12 years. (Approved 7/29/2022, Arcutis Biotherapeutics, Inc.) Please click here for full prescribing information.

Major Depressive Disorder (MDD): Dextromethorphan and Bupropion Extended-Release Tablets (Auvelity^®) (formerly AXS-05)

The first and only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for the treatment of MDD in adults and uses the first new oral nonmonoamine-based mechanism of action approved in more than 60 years. It is also the first and only rapid-acting medicine approved to treat MDD labeled with statistically significant antidepressant efficacy vs placebo starting at 1 week. (Approved 8/18/2022; Axsome Therapeutics, Inc.) Please click here for full prescribing information

Plaque Psoriasis: Deucravacitinib Tablets (Sotyktu^®)

A tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is the only approved TYK2 inhibitor globally and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly a decade. It is not recommended for use in combination with other potent immunosuppressants. (Approved 9/9/2022; Bristol Myers Squibb) Please click here for full prescribing information.